Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Work In Process (2021 - 2025)

Dr Reddys Laboratories (RDY) has 4 years of Work In Process data on record, last reported at $171.3 million in Q1 2024.

  • For Q1 2024, Work In Process rose 20.34% year-over-year to $171.3 million; the TTM value through Mar 2024 reached $171.3 million, up 20.34%, while the annual FY2024 figure was $171.8 million, 17.83% up from the prior year.
  • Work In Process reached $171.3 million in Q1 2024 per RDY's latest filing, up from $142.3 million in the prior quarter.
  • Across five years, Work In Process topped out at $171.4 million in Q1 2022 and bottomed at $137.3 million in Q1 2021.
  • Average Work In Process over 4 years is $155.6 million, with a median of $156.8 million recorded in 2023.
  • Peak YoY movement for Work In Process: rose 24.84% in 2022, then fell 16.96% in 2023.
  • A 4-year view of Work In Process shows it stood at $137.3 million in 2021, then grew by 24.84% to $171.4 million in 2022, then dropped by 16.96% to $142.3 million in 2023, then rose by 20.34% to $171.3 million in 2024.
  • Per Business Quant database, its latest 3 readings for Work In Process were $171.3 million in Q1 2024, $142.3 million in Q1 2023, and $171.4 million in Q1 2022.